Dyax's HAE drug succeeds in second Phase III trial
This article was originally published in Scrip
Executive Summary
Dyax's lead investigational hereditary angioedema (HAE) drug DX-88 (ecallantide) has met the primary endpoint of its second Phase III trial, and the company intends to submit a BLA to the FDA early in the fourth quarter of 2008. Shares in the US-based biotech company rose 15% on the news of the trial results, closing at $5.00 on Nasdaq on August 18th.